Safety and Effectiveness of Edoxaban in Japanese Patients With Venous Thromboembolism ― An Interim Analysis of Data From a Japanese Postmarketing Observational Study (ETNA-VTE-Japan) ―
Open Access
- 24 May 2019
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 83 (6), 1394-1404
- https://doi.org/10.1253/circj.cj-18-1362
Abstract
Background:ETNA-VTE-Japan is an ongoing prospective observational study conducted as part of a postmarketing observational study to investigate the safety and effectiveness of edoxaban in Japanese patients for whom the drug has been newly prescribed to treat venous thromboembolism (VTE) and prevent VTE recurrence. The results of an interim analysis of data collected at 3 months are presented. Methods and Results:A total of 1,732 patients were enrolled. The safety and effectiveness analyses included data from 1,703 and 1,699 patients, respectively. In the safety analysis set, 39.4% of patients were aged ≥75 years, 58.2% had body weight ≤60 kg, and 22.2% had creatinine clearance Conclusions:The results confirm no major concerns about the safety and effectiveness of edoxaban in Japanese patients with VTE in the first 3 months of treatment. (Trial registration No.: UMIN000016387.)Keywords
This publication has 26 references indexed in Scilit:
- Incidence, Characteristics and Management of Venous Thromboembolism in Japan During 2011Circulation Journal, 2018
- Edoxaban: An Update on the New Oral Direct Factor Xa InhibitorDrugs, 2014
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismThe New England Journal of Medicine, 2013
- Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy SubjectsClinical Pharmacology in Drug Development, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismThe New England Journal of Medicine, 2010
- Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy VolunteersThe Journal of Clinical Pharmacology, 2010
- Venous Thromboembolism Deep Vein Thrombosis With Pulmonary Embolism, Deep Vein Thrombosis Alone, and Pulmonary Embolism AloneCirculation Journal, 2009
- Venous thromboembolism (VTE) in EuropeThrombosis and Haemostasis, 2007